Clinical trials: Hepatecellular Carcinoma
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Hepatecellular Carcinoma
Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
1.1. Main Objectives The objective response rate (ORR) determined by the researchers based on RECIST v1.1 was used to evaluate the efficacy of systemic therapy (carrycept combined with apatinib) in combination with or without…
- Trial name
- NCT07482670
- Volunteers
- 32 people
- Sponsor
- Xiangya Hospital of Central South University
Hepatecellular Carcinoma
Affordable Made-in-India Microspheres for Liver Cancer Therapy
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortality.HCC remains the leading causes of cancer-related deaths worldwide…
- Trial name
- ReLIVE (NCT07436988)
- Testing
- 90Y-Theraspheres, 188Re-Microspheres
- Where
- 5 sites in India
- Volunteers
- 18 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver…
- Conditions
- Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
- Trial name
- NCT07327788
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatecellular Carcinoma, Cirrhosis
STOP HCC-GAAD-APAC-Thailand
Hepatocellular carcinoma (HCC) surveillance is frequently underutilized, and currently available biomarkers, such as alpha-fetoprotein (AFP), demonstrate suboptimal diagnostic performance.
- Conditions
- Hepatecellular Carcinoma, Cirrhosis, HBV Infection
- Trial name
- NCT07319299
- Testing
- GAAD score
- Where
- Thailand
- Volunteers
- 2,100 people
- Sponsor
- Mahidol University
Hepatecellular Carcinoma, Liver Injury
HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival
The purpose of this study is to compare the liver injury induced by HAIC combined with PD-1/PD-L1 inhibitors and TKIs versus triple therapy with TACE in the treatment of patients with advanced HCC; to compare the efficacy of the…
- Conditions
- Hepatecellular Carcinoma, Liver Injury, HAIC(Hepatic Artery Infusion Chemotherapy), TACE(Transcatheter Arterial Chemoembolization)
- Trial name
- NCT07277192
- Where
- China
- Volunteers
- 562 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatecellular Carcinoma, Hepatectomy
AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
This observational study aims to validate a deep learning model for predicting aggressive recurrence patterns in patients with early-stage liver cancer (HCC) after surgery.
- Trial name
- NCT07062380
- Testing
- Curative liver resection, Real-world multimodal therapy
- Where
- China
- Volunteers
- 353 people
- Sponsor
- Tongji Hospital
Hepatectomy, Hepatecellular Carcinoma
Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma
Selection criteria for safe hepatectomy for HCC are not well established. The aim of this study was the validation of the selection criteria for safe hepatectomy for hepatocellular carcinoma.
- Conditions
- Hepatectomy, Hepatecellular Carcinoma, Cirrhosis
- Trial name
- NCT02056041
- Testing
- Hepatectomy
- Where
- Italy
- Volunteers
- 336 people
- Sponsor
- University of Milan